Efficacy of composite lactobacillus in patients with non-alcoholicfatty liver disease

Objective To investigate the efficacy of composite lactobacillus in patients with non-alcoholic fatty liver disease. Methods From June 2011 to June 2014, 114 patients with non-alcoholic fatty liver disease in our hospital were chosen as research objects. All patients were randomly divided into observation group (n=57) and control group (n=57). Patients in observation group received composite lactobacillus (0.66 g, 3/d, 16 weeks) combined with life-style intervention, while patients in control group only received life-style intervention. After 16 weeks of treatment, the differences of liver function, serum lipid levels, inflammatory cytokines, body mass index, insulin resistance index and treatment effect before and after treatment in observation group and control group were compared. Results After treatment, the serum alanine aminotransferase (ALT, control group 86.65±28.34 vs 76.19±23.32; observation group 85.41±27.59 vs 66.81±26.76), aspartate aminotransferase (AST, control group 69.73±24.74 vs 60.49±18.15; observation group 68.35±26.62 vs 53.12±19.59), triglycerides (TG, control group 3.59±0.48 vs 3.35±0.43; observation group 3.75±0.46 vs 2.83±0.37), total cholesterol (TC, control group 6.17±0.76 vs 5.83±0.52; observation group 6.15±0.81 vs 5.54±0.69), interleukins-6 (IL-6, control group 135.64±12.14 vs 129.94±11.36; observation group 133.67±13.25 vs 97.86±11.82), tumor necrosis factor-α (TNF-α, control group 10.69±3.23 vs 8.84±3.17; observation group 10.68±3.43 vs 7.29±1.75), body mass index (BMI, control group 31.34±2.35 vs 30.02±2.31; observation group 31.58±2.36 vs 28.12±2.23), insulin resistance index (IR, control group 2.77±0.38 vs 2.62±0.34; observation group 2.79±0.39 vs 2.46±0.33) in both observation group and control group were lower than before treatment (P< 0.05), and the observation group (ALT: 66.81±26.76; AST: 53.12±19.59; TG: 2.83±0.37; TC: 5.54±0.69; IL-6: 97.86±11.82; TNF-α: 7.29±1.75; BMI: 28.12±2.23; IR: 2.46±0.33) decreased more significantly than control group (ALT: 76.19±23.32; AST: 60.49±18.15; TG: 3.35±0.43; TC: 5.83±0.72; IL-6: 129.94±11.36; TNF-α: 8.84±3.17; BMI: 30.02±2.31; IR: 2.62±0.34, P< 0.05). The curative effect in observation group were superior to control group (73.68% vs 36.84%), P< 0.05). Conclusion Composite lactobacillus can improve liver function, serum lipid levels, inflammatory cytokines, body mass index, insulin resistance index and its treatment effect is significant.